No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
PRME Prime Medicine
- 3.350
- +0.360+12.04%
Close Jan 3 16:00 ET
- 3.330
- -0.020-0.60%
Post 20:01 ET
439.39MMarket Cap-1.63P/E (TTM)
3.370High3.030Low749.21KVolume3.050Open2.990Pre Close2.41MTurnover1.17%Turnover RatioLossP/E (Static)131.16MShares9.77052wk High2.32P/B214.86MFloat Cap2.56052wk Low--Dividend TTM64.14MShs Float21.730Historical High--Div YieldTTM11.37%Amplitude2.560Historical Low3.222Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now?
We Think Prime Medicine (NASDAQ:PRME) Needs To Drive Business Growth Carefully
Express News | Prime Medicine Inc Files for Resale of up to 11 Mln Common Shares by the Selling Stockholder - SEC Filing
Prime Medicine Initiated at Market Outperform by JMP Securities
JMP Securities Initiates Prime Medicine(PRME.US) With Buy Rating, Announces Target Price $10
Prime Medicine, Inc.: Innovative Gene Editing Platform With Significant Market Potential
Heat List
US
Overall
Symbol
Price
% Chg
No Data
